BACKGROUND: In inflammatory bowel disease (IBD), cytokine levels (such as interleukin-1 (IL-1)) are elevated. We have shown previously that IL-1 activates phospholipid signaling pathways in intestinal epithelial cells (EEC), leading to increased ceramide levels. AIM: To determine whether ceramide induces apoptosis in IEC. METHODS: Apoptosis was evaluated by annexin-V binding or Hoechst nuclear staining. Levels of bcl-2, bcl-x, bax, p53 and p21 were determined by Western blotting, and celi cycle analysis was determined by flow cytometry. RESULTS: IL-1 increased ceramide accumulation in a time-dependent and concentration-dependent manner with a peak response at 4 h, with [IL-1] = 30 ng/ml. Neither IL-1 nor ceramide induced apoptosis in EEC, but they increased bcl-2 levels and decreased bax and p21 levels without affecting bcl-x and p53 levels. They also caused a slight but significant increase in the G2/M phase. These data suggest a role for ceramide in IBD and suggest a possible mechanism for the enhanced tumorigenic activity in IBD patients.
BACKGROUND: In inflammatory bowel disease (IBD), cytokine levels (such as interleukin-1 (IL-1)) are elevated. We have shown previously that IL-1 activates phospholipid signaling pathways in intestinal epithelial cells (EEC), leading to increased ceramide levels. AIM: To determine whether ceramide induces apoptosis in IEC. METHODS: Apoptosis was evaluated by annexin-V binding or Hoechst nuclear staining. Levels of bcl-2, bcl-x, bax, p53 and p21 were determined by Western blotting, and celi cycle analysis was determined by flow cytometry. RESULTS: IL-1 increased ceramide accumulation in a time-dependent and concentration-dependent manner with a peak response at 4 h, with [IL-1] = 30 ng/ml. Neither IL-1 nor ceramide induced apoptosis in EEC, but they increased bcl-2 levels and decreased bax and p21 levels without affecting bcl-x and p53 levels. They also caused a slight but significant increase in the G2/M phase. These data suggest a role for ceramide in IBD and suggest a possible mechanism for the enhanced tumorigenic activity in IBD patients.
Authors: M Verheij; R Bose; X H Lin; B Yao; W D Jarvis; S Grant; M J Birrer; E Szabo; L I Zon; J M Kyriakis; A Haimovitz-Friedman; Z Fuks; R N Kolesnick Journal: Nature Date: 1996-03-07 Impact factor: 49.962
Authors: S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks Journal: Science Date: 1994-11-04 Impact factor: 47.728
Authors: A Haimovitz-Friedman; C C Kan; D Ehleiter; R S Persaud; M McLoughlin; Z Fuks; R N Kolesnick Journal: J Exp Med Date: 1994-08-01 Impact factor: 14.307
Authors: Wim J van Blitterswijk; Arnold H van der Luit; Robert Jan Veldman; Marcel Verheij; Jannie Borst Journal: Biochem J Date: 2003-01-15 Impact factor: 3.857
Authors: Kajsa Kajander; Eveliina Myllyluoma; Sinikka Kyrönpalo; Martin Rasmussen; Pentti Sipponen; Ismo Mattila; Tuulikki Seppänen-Laakso; Heikki Vapaatalo; Matej Oresic; Riitta Korpela Journal: World J Gastroenterol Date: 2009-12-28 Impact factor: 5.742
Authors: Riina-A Kekkonen; Marko Sysi-Aho; Tuulikki Seppanen-Laakso; Ilkka Julkunen; Heikki Vapaatalo; Matej Oresic; Riitta Korpela Journal: World J Gastroenterol Date: 2008-05-28 Impact factor: 5.742
Authors: Ahmad W Husari; Ghassan S Dbaibo; Hala Bitar; Aline Khayat; Shoghag Panjarian; Michel Nasser; Fadi F Bitar; Marwan El-Sabban; Ghazi Zaatari; Salman M Mroueh Journal: Respir Res Date: 2006-07-26